-+ 0.00%
-+ 0.00%
-+ 0.00%
Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19
Share
Listen to the news
Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending